NOXOPHARM LIMITED
ASX:NOXPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 99.6% of what they think they own, once every option and right converts.
In a trading halt since 27 Oct 2026: “Pending release of an announcement regarding a material Capital Raising” · expected to resume 29 Oct 2026
Runway under 2 quarters
Low because 5 of its 6 signals are quiet.
NOXOPHARM LIMITED's ordinary share count stood at 307M as of February 2026, the only share-count filing on record; the company has not lodged any new share-issuance filings since January 2024. No capital has been raised through cash placements, rights issues or share purchase plans in the past 24 months. Options and rights on issue could convert into 1M new shares, representing 0.4% of the current share count, with no in-the-money options and the nearest expiry in September 2027. The most recent cash report was for the June 2026 quarter, but at the reported spend rate the reported cash would since have been used up, and no later cash report is on record, so no funding-runway figure applies. No proposed securities issues are currently pending.
Quick answers · 4
Why is NOX in a trading halt?
Noxopharm requested a trading halt on 27 Oct 2026, giving the reason "Pending release of an announcement regarding a material Capital Raising". Trading was expected to resume 29 Oct 2026.
How much placement capacity does NOX have left?
None of the 15% placement capacity counted as used in the last 12 months (estimate). Under ASX Listing Rule 7.1 a company may place up to 15% of its shares in 12 months without shareholder approval.
How much cash does NOX have?
In its quarterly cash report for the quarter ended 30 June 2026, Noxopharm reported $293k of cash and estimated 6.2 quarters of funding available at its current rate of spending. That is the company's own estimate.
When do NOX's options expire?
Unexercised options and rights equal 0.4% of Noxopharm's shares on issue; the nearest expiry is Sept 2027.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2AThe form a company lodges to have new securities quoted on the ASX. It restates how many of each class are on issue. quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 27 Feb 2026 | 2A · quoted issue | NOX : ORDINARY FULLY PAID | 307.2M | Appendix 2A |
| 2 Jan 2026 | 3H · cancellation | NOX : ORDINARY FULLY PAID | 292.2M | Appendix 3H |
| 2 Jan 2026 | 3G · unquoted | ORDINARY FULLY PAID | 292.2M | Appendix 3G |
| 12 Dec 2025 | 3G · unquoted | ORDINARY FULLY PAID | 292.2M | Appendix 3G |
| 10 Jan 2025 | 3G · unquoted | NOX : ORDINARY FULLY PAID | 292.2M | Appendix 3G |
Securities on issue over time
Ordinary shares and every option and rights class, month by month over two years. The top edge is the fully diluted count.
Capital raises
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 / 7.1ARule 7.1 lets a company issue up to 15% of its shares in 12 months without a shareholder vote. Rule 7.1A adds 10% for smaller companies whose holders approve it. allows 15% of ordinary securities in any 12 months, and every Appendix 3BNotice that a company proposes to issue new securities, such as a placement. The securities are not on issue until a later filing confirms it. states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
At $0.049 today, 0 securities are in the money (0.0% of shares on issue). No more priced supply until 5× today’s price, which takes it to 1.3M (0.4% of shares).
- Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| NOXAI | Options | Price-triggered | $0.15 | 10 Sept 2027 | 1.3M | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column. For what expires soon across other listed companies, see the options expiry calendar.
- NOXAHconvertible notes3.9M27 Feb 2026 Appendix 2A
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 25 May 2026 | Boris Patkin | Other off-market | — | — | — | $38k | 3Y notice |
| 12 Dec 2025 | Fred Bart | Other | — | 250k | 1.3M | $1.3M | 3Y notice |
| 6 Nov 2024 | Gisela Mautner | Sell | — | 135k | — | — | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 Oct 2026.